The Indiana boy driving CGT development

Sean Werner has that calm, understated Midwestern style that instantly puts you at ease. But beneath that relaxed manner is someone who has built a career across science, regulatory strategy, cell therapy and leadership, from Eli Lilly to leading a spinout and then into BioLife Solutions after its acquisition of Sexton Biotechnologies.

What I learnt

One of the biggest takeaways from this conversation was the jump from scientist to business leader. Sean spoke really well about how scientific training teaches caution and precision, while leadership often demands conviction and decisions before you have every answer. That is a big shift and he captured it brilliantly.

I also liked his view on decision making. If a decision is reversible, do not get stuck. Move, learn and adjust. That is such a useful lesson for leaders, especially in young companies where speed and clarity matter.

His perspective on cryopreservation was also a strong reminder that some of the most important parts of drug development are often the least glamorous. Sean made a compelling case that this remains an overlooked part of cell therapy development, despite its huge influence on performance and scalability.

And on cell and gene therapy more broadly, he was refreshingly balanced. He acknowledged the tougher market, but still made a strong case for optimism. Not hype. Not denial. Just a grounded belief that the sector is still progressing and will likely branch into more specialised and impactful applications over time.

What I liked

I liked Sean’s curious nature. His career feels shaped by following interesting problems rather than chasing titles.

I also liked how relaxed and understated he is. He does not oversell. He does not force the point. He just comes across as thoughtful, capable and quietly credible.

And he clearly cares. About the science, about helping companies do things better, and ultimately about the therapies reaching patients in the best possible way.

Reflection

Sean’s story is a reminder that the future of CGT will not just be shaped by breakthrough science. It will also be shaped by the people who understand process, execution and how to make these therapies work in the real world.

🎧 Hear the full episode here: Apple | Spotify

He feels like one of those people. Calm, credible and focused on what actually matters.As always, thank you to our sponsors Bora Pharmaceuticals and Lead Candidate for supporting Molecule to Market